Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 18 U.S.C. §208(b)(3)

Ralph D'Agostino, Ph.D.			
Committee: Meeting Date:	The Oncologic Drugs Advisory Committee March 13, 2006		
I acknowledge that contingent upon public disclosure of the financial interest listed below, related to NDA 20-509, S-039 Gemzar (Gemcitabine HCl), sponsored by Eli Lilly & Company, proposed indication: for use in combination with Carboplatin for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).			
Type of Interest	Nature	Magnitude	
Advisory Board (unrelated)	Competitor	Less than \$10,001	
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.			
//S// Signature of SGE		<u>2/9/06</u> Date	